Can metabolically healthy obesity be explained by diet, genetics, and inflammation?

Molecular Nutrition and Food Research

Volumn 59, Issue 1, 2015, Pages 75-93

  Navarro, Estanislau ^a   Funtikova, Anna N ^b,c,d   Fíto, Montserrat ^b,c   Schröder, Helmut ^b,c  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Genetics of obesity; Inflammation; Metabolically healthy obesity; NcRNAs; Nutrition

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; PLANT MEDICINAL PRODUCT; POLYPHENOL; UNSATURATED FATTY ACID; VITAMIN;

ADIPOSE TISSUE; ANIMAL; CLINICAL TRIAL (TOPIC); DIET; DISEASE MODEL; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; HUMAN; INFLAMMATION; LIFESTYLE; METABOLISM; OBESITY; PHENOTYPE;

ADIPOSE TISSUE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; DIET; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; FATTY ACIDS, UNSATURATED; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; LIFE STYLE; OBESITY; PHENOTYPE; PHYTOCHEMICALS; POLYPHENOLS; VITAMINS;

EID: 84921059459     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201400521     Document Type: Review

References (234)

1. Grundy, S. M., Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 2004, 89, 2595-2600.
2. Dorresteijn, J. A., Visseren, F. L., Spiering, W., Mechanisms linking obesity to hypertension. Obes. Rev. 2012, 13, 17-26.
3. Schienkiewitz, A., Schulze, M. B., Hoffmann, K., Kroke, A. et al., Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. Am. J. Clin. Nutr. 2006, 84, 427-433.
4. WHO Obesity and overweight (2013) Fact sheet N°311. http://www.who.int/mediacentre/factsheets/fs311/en/, last accessed August 2014.
5. Withrow, D., Alter, D. A., The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes. Rev. 2011, 12, 131-141.
6. Calder, P. C., Albers, R., Antoine, J. M., Blum, S. et al., Inflammatory disease processes and interactions with nutrition. Br. J. Nutr. 2009, 101(Suppl 1), S1-45.
7. Gregor, M. F., Hotamisligil, G. S., Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 2011, 29, 415-445.
8. Hosogai, N., Fukuhara, A., Oshima, K., Miyata, Y. et al., Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007, 56, 901-911.
9. Santos, S., Oliveira, A., Lopes, C., Systematic review of saturated fatty acids on inflammation and circulating levels of adipokines. Nutr. Res. 2013, 33, 687-695.
10. Fan, C., Zirpoli, H., Qi, K., n-3 fatty acids modulate adipose tissue inflammation and oxidative stress. Curr. Opin. Clin. Nutr. Metab. Care 2013, 16, 124-132.
11. Calder, P. C., Long chain fatty acids and gene expression in inflammation and immunity. Curr.Opin.Clin. Nutr. Metab. Care 2013, 16, 425-433.
12. Wan, Y., Wang, G., Chen, S. D., Genetic predisposition to inflammation: a new risk factor of Alzheimer's disease. Neurosci. Bull. 2008, 24, 314-322.
13. Tousoulis, D., Androulakis, E., Papageorgiou, N., Miliou, A. et al., Genetic predisposition to left ventricular hypertrophy and the potential involvement of cystatin-C in untreated hypertension. Am. J. Hypertens. 2013, 26, 683-690.
14. Bennermo, M., Held, C., Stemme, S., Ericsson, C. G. et al., Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases? Clin. Chem. 2004, 50, 2136-2140.
15. Primeau, V., Coderre, L., Karelis, A. D., Brochu, M. et al., Characterizing the profile of obese patients who are metabolically healthy. Int. J. Obes. (Lond) 2011, 35, 971-981.
16. Velho, S., Paccaud, F., Waeber, G., Vollenweider, P. et al., Metabolically healthy obesity: different prevalences using different criteria. Eur. J. Clin. Nutr. 2010, 64, 1043-1051.
17. van Vliet-Ostaptchouk, J. V., Nuotio, M. L., Slagter, S. N., Doiron, D. et al., The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr. Disord. 2014, 14, 9.
18. Schröder, H., Ramos, R., Baena-Díez, J. M., Mendez M. A. et al., Determinants of the transition from a cardiometabolic normal to abnormal overweight/obese phenotype in a Spanish population. Eur. J. Nutr. 2013, 53, 1345-1353.
19. Soriguer, F., Gutiérrez-Repiso, C., Rubio-Martín, E., García-Fuentes, E. et al., Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. J. Clin. Endocrinol. Metab. 2013, 98, 2318-2325.
20. Appleton, S. L., Seaborn, C. J., Visvanathan, R., Hill, C. L. et al., Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care 2013, 36, 2388-2394.
21. Prince, R. L., Kuk, J. L., Ambler, K. A., Dhaliwal, J. et al., Predictors of metabolically healthy obesity in children. Diabetes Care 2014, 37, 1462-1468.
22. Kramer, C. K., Zinman, B., Retnakaran, R., Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. Ann. Intern. Med. 2013, 159, 758-769.
23. Stefan, N., Häring, H. U., Hu, F. B., Schulze, M. B., Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diab. Endocrinol.2013, 1, 152-162.
24. Ortega, F. B., Lee, D. C., Katzmarzyk, P. T., Ruiz, J. R. et al., The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. Eur. Heart. J. 2013, 34, 389-397.
25. Hamer, M., Stamatakis, E., Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J. Clin. Endocrinol.Metab. 2012, 97, 2482-2488.
26. Mørkedal, B., Vatten, L. J., Romundstad, P. R., Laugsand, L. E. et al., Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trøndelag Health Study), Norway. J. Am. Coll. Cardiol. 2014, 63, 1071-1078.
27. Voulgari, C., Tentolouris, N., Dilaveris, P., Tousoulis, D. et al., Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals. J. Am. Coll. Cardiol. 2011, 58, 1343-1350.
28. Wang, F., Deeney, J. T., Denis, G. V., Brd2 gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes. Vitam. Horm. 2013, 91, 49-75.
29. Farooqi, I. S., O'Rahilly, S., Monogenic obesity in humans. Annu. Rev. Med. 2005, 56, 443-458.
30. Fall, T., Ingelsson, E., Genome-wide association studies of obesity and metabolic syndrome. Mol. Cell Endocrinol. 2014, 382, 740-757.
31. Dina, C., Meyre, D., Gallina, S., Durand, E. et al., Variation in FTO contributes to childhood obesity and severe adult obesity. Nat. Genet. 2007, 39, 724-726.
32. Frayling, T. M., Timpson, N. J., Weedon, M. N., Zeggini, E. et al., A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007, 316, 889-894.
33. Benzinou, M., Chevre, J. C., Ward, K. J., Lecoeur, C. et al., Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. Hum. Mol. Genet. 2008, 17, 1916-1921.
34. Loos, R. J., Lindgren, C. M., Li, S., Wheeler, E. et al., Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat. Genet. 2008, 40, 768-775.
35. Willer, C. J., Speliotes, E. K., Loos, R. J., Li, S. et al., Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat. Genet. 2009, 41, 25-34.
36. Meyre, D., Delplanque, J., Chevre, J. C., Lecoeur, C. et al., Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat. Genet. 2009, 41, 157-159.
37. Burgdorf, K. S., Gjesing, A. P., Grarup, N., Justesen, J. M. et al., Association studies of novel obesity-related gene variants with quantitative metabolic phenotypes in a population-based sample of 6039 Danish individuals. Diabetologia 2012, 55, 105-113.
38. Dick, K. J., Nelson, C. P., Tsaprouni, L., Sandling, J. K. et al., DNA methylation and body-mass index: a genome-wide analysis. Lancet 2014, 383, 1990-1998.
39. Li, S., Zhao, J. H., Luan, J., Luben, R. N. et al., Cumulative effects and predictive value of common obesity-susceptibility variants identified by genome-wide association studies. Am. J. Clin. Nutr. 2010, 91, 184-190.
40. Speliotes, E. K., Willer, C. J., Berndt, S. I., Monda, K. L. et al., Association analyses of 249796 individuals reveal 18 new loci associated with body mass index. Nat. Genet. 2010, 42, 937-948.
41. Hebebrand, J., Volckmar, A. L., Knoll, N., Hinney, A., Chipping away the 'missing heritability': GIANT steps forward in the molecular elucidation of obesity - but still lots to go. Obes. Facts 2010, 3, 294-303.
42. Schwenk, R. W., Vogel, H., Schurmann, A., Genetic and epigenetic control of metabolic health. Mol. Metab. 2013, 2, 337-347.
43. Leung, A., Parks, B. W., Du, J., Trac, C. et al., Open chromatin profiling in mice livers reveals unique chromatin variations induced by high fat diet. J. Biol. Chem. 2014, 289, 23557-23567.
44. Belkina, A. C., Denis, G. V., Obesity genes and insulin resistance. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17, 472-477.
45. Xu, H., Barnes, G. T., Yang, Q., Tan, G. et al., Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112, 1821-1830.
46. Olefsky, J. M., Glass, C. K., Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 2010, 72, 219-246.
47. Denis, G. V., Obin, M. S., 'Metabolically healthy obesity': origins and implications. Mol. Aspects Med. 2013, 34, 59-70.
48. Musri, M. M., Gomis, R., Parrizas, M., A chromatin perspective of adipogenesis. Organogenesis 2010, 6, 15-23.
49. Belkina, A. C., Denis, G. V., BET domain co-regulators in obesity, inflammation and cancer. Nat. Rev. Cancer 2012, 12, 465-477.
50. Denis, G. V., Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation. Discov. Med. 2010, 10, 489-499.
51. Wang, F., Liu, H., Blanton, W. P., Belkina, A. et al., Brd2 disruption in mice causes severe obesity without Type 2 diabetes. Biochem. J. 2010, 425, 71-83.
52. Belkina, A. C., Nikolajczyk, B. S., Denis, G. V., BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J. Immunol. 2013, 190, 3670-3678.
53. Stolarczyk, E., Vong, C. T., Perucha, E., Jackson, I. et al., Improved insulin sensitivity despite increased visceral adiposity in mice deficient for the immune cell transcription factor T-bet. Cell Metab. 2013, 17, 520-533.
54. Meissburger, B., Ukropec, J., Roeder, E., Beaton, N. et al., Adipogenesis and insulin sensitivity in obesity are regulated by retinoid-related orphan receptor gamma. EMBO Mol. Med. 2011, 3, 637-651.
55. Glass, C. K., Saijo, K., Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat. Rev. Immunol. 2010, 10, 365-376.
56. Li, P., Spann, N. J., Kaikkonen, M. U., Lu, M. et al., NCoR repression of LXRs restricts macrophage biosynthesis of insulin-sensitizing omega 3 fatty acids. Cell 2013, 155, 200-214.
57. Ballak, D. B., van Diepen, J. A., Moschen, A. R., Jansen, H. J. et al., IL-37 protects against obesity-induced inflammation and insulin resistance. Nat. Commun. 2014, 5, 4711.
58. Jia, L., Vianna, C. R., Fukuda, M., Berglund, E. D. et al., Hepatocyte Toll-like receptor 4 regulates obesity-induced inflammation and insulin resistance. Nat. Commun. 2014, 5, 3878.
59. Carthew, R. W., Sontheimer, E. J., Origins and mechanisms of miRNAs and siRNAs. Cell 2009, 136, 642-655.
60. Xie, H., Lim, B., Lodish, H. F., MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 2009, 58, 1050-1057.
61. Zaragosi, L. E., Wdziekonski, B., Brigand, K. L., Villageois, P. et al., Small RNA sequencing reveals miR-642a-3p as a novel adipocyte-specific microRNA and miR-30 as a key regulator of human adipogenesis. Genome Biol. 2011, 12, R64.
62. Song, G., Xu, G., Ji, C., Shi, C. et al., The role of microRNA-26b in human adipocyte differentiation and proliferation. Gene 2014, 533, 481-487.
63. Lee, E. K., Lee, M. J., Abdelmohsen, K., Kim, W. et al., miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. Mol. Cell Biol. 2011, 31, 626-638.
64. Lin, Q., Gao, Z., Alarcon, R. M., Ye, J. et al., A role of miR-27 in the regulation of adipogenesis. FEBS J. 2009, 276, 2348-2358.
65. Mori, M., Nakagami, H., Rodriguez-Araujo, G., Nimura, K. et al., Essential role for miR-196a in brown adipogenesis of white fat progenitor cells. PLoS Biol. 2012, 10, e1001314.
66. Kim, H. J., Cho, H., Alexander, R., Patterson, H. C. et al., MicroRNAs are required for the feature maintenance and differentiation of brown adipocytes. Diabetes 2014, 63, 4045-4056.
67. Sun, L., Xie, H., Mori, M. A., Alexander, R. et al., Mir193b-365 is essential for brown fat differentiation. Nat. Cell Biol. 2011, 13, 958-965.
68. Yin, H., Pasut, A., Soleimani, V. D., Bentzinger, C. F. et al., MicroRNA-133 controls brown adipose determination in skeletal muscle satellite cells by targeting Prdm16. Cell Metab. 2013, 17, 210-224.
69. Harms, M. J., Ishibashi, J., Wang, W., Lim, H. W. et al., Prdm16 is required for the maintenance of brown adipocyte identity and function in adult mice. Cell Metab. 2014, 19, 593-604.
70. Williams, M. D., Mitchell, G. M., MicroRNAs in insulin resistance and obesity. Exp. Diabetes Res. 2012, 2012, 484696.
71. Trajkovski, M., Hausser, J., Soutschek, J., Bhat, B. et al., MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011, 474, 649-653.
72. Yang, W. M., Jeong, H. J., Park, S. Y., Lee, W., Saturated fatty acid-induced miR-195 impairs insulin signaling and glycogen metabolism in HepG2 cells. FEBS Lett. 2014, 588, 3939-3946.
73. Jordan, S. D., Kruger, M., Willmes, D. M., Redemann, N. et al., Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat. Cell Biol. 2011, 13, 434-446.
74. Zhou, B., Li, C., Qi, W., Zhang, Y. et al., Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia 2012, 55, 2032-2043.
75. Kornfeld, J. W., Baitzel, C., Konner, A. C., Nicholls, H. T. et al., Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. Nature 2013, 494, 111-115.
76. Horikawa, Y., Iwasaki, N., Hara, M., Furuta, H. et al., Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat. Genet. 1997, 17, 384-385.
77. Kim, C., Lee, H., Cho, Y. M., Kwon, O. J. et al., TNFalpha-induced miR-130 resulted in adipocyte dysfunction during obesity-related inflammation. FEBS Lett. 2013, 587, 3853-3858.
78. Hulsmans, M., Van Dooren, E., Mathieu, C., Holvoet, P., Decrease of miR-146b-5p in monocytes during obesity is associated with loss of the anti-inflammatory but not insulin signaling action of adiponectin. PLoS One 2012, 7, e32794.
79. Shi, C., Zhu, L., Chen, X., Gu, N. et al., IL-6 and TNF-alpha induced obesity-related inflammatory response through transcriptional regulation of miR-146b. J. Interferon Cytokine Res. 2014, 34, 342-348.
80. Shi, X., Sun, M., Liu, H., Yao, Y. et al., Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013, 339, 159-166.
81. Sun, L., Goff, L. A., Trapnell, C., Alexander, R. et al., Long noncoding RNAs regulate adipogenesis. Proc. Natl. Acad. Sci. USA 2013, 110, 3387-3392.
82. Zhang, J., Cui, X., Shen, Y., Pang, L. et al., Distinct expression profiles of LncRNAs between brown adipose tissue and skeletal muscle. Biochem. Biophys. Res. Commun. 2014, 443, 1028-1034.
83. Yi, F., Yang, F., Liu, X., Chen, H. et al., RNA-seq identified a super-long intergenic transcript functioning in adipogenesis. RNA Biol. 2013, 10, 991-1001.
84. Zhao, X. Y., Li, S., Wang, G. X., Yu, Q. et al., A long noncoding RNA transcriptional regulatory circuit drives thermogenic adipocyte differentiation. Mol. Cell 2014, 55, 372-382.
85. Xu, B., Gerin, I., Miao, H., Vu-Phan, D. et al., Multiple roles for the non-coding RNA SRA in regulation of adipogenesis and insulin sensitivity. PLoS One 2010, 5, e14199.
86. Liu, S., Sheng, L., Miao, H., Saunders, T. L. et al., SRA gene knockout protects against diet-induced obesity and improves glucose tolerance. J. Biol. Chem. 2014, 289, 13000-13009.
87. Buermans, H. P., den Dunnen, J. T., Next generation sequencing technology: advances and applications. Biochim. Biophys Acta 2014, 1842, 1932-1941.
88. Alexander, R., Lodish, H., Sun, L., MicroRNAs in adipogenesis and as therapeutic targets for obesity. Expert. Opin. Ther. Targets 2011, 15, 623-636.
89. Ge, Q., Brichard, S., Yi, X., Li, Q., microRNAs as a new mechanism regulating adipose tissue inflammation in obesity and as a novel therapeutic strategy in the metabolic syndrome. J. Immunol. Res. 2014, 2014, 987285.
90. Milagro, F. I., Mansego, M. L., De Miguel, C., Martinez, J. A., Dietary factors, epigenetic modifications and obesity outcomes: progresses and perspectives. Mol. Aspects Med. 2013, 34, 782-812.
91. Neeha, V. S., Kinth, P., Nutrigenomics research: a review. J. Food Sci. Technol. 2013, 50, 415-428.
92. McKay, J. A., Mathers, J. C., Diet induced epigenetic changes and their implications for health. Acta Physiol. (Oxf.) 2011, 202, 103-118.
93. Ho, E., Clarke, J. D., Dashwood, R. H., Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J. Nutr. 2009, 139, 2393-2396.
94. Milenkovic, D., Jude, B., Morand, C., miRNA as molecular target of polyphenols underlying their biological effects. Free Radic. Biol. Med. 2013, 64, 40-51.
95. Palmer, J. D., Soule, B. P., Simone, B. A., Zaorsky, N. G. et al., MicroRNA expression altered by diet: can food be medicinal? Ageing Res. Rev. 2014, 17, 16-24.
96. Ouchi, N., Parker, J. L., Lugus, J. J., Walsh, K., Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11, 85-97.
97. Phillips, C. M., Perry, I. J., Does inflammation determine metabolic health status in obese and nonobese adults? J. Clin. Endocrinol.Metab. 2013, 98, E1610-1619.
98. De Nardo, D., Latz, E., NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 2011, 32, 373-379.
99. Esser, N., L'homme, L., De Roover, A., Kohnen, L. et al., Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia. 2013, 56, 2487-2497.
100. Trayhurn, P., Hypoxia and adipose tissue function and dysfunction in obesity. Physiol. Rev. 2013, 93, 1-21.
101. Eltzschig, H. K., Carmeliet, P., Hypoxia and inflammation. N. Engl. J. Med. 2011, 364, 656-665.
102. Tynan, G. A., Hearnden, C. H., Oleszycka, E., Lyons, C. L. et al., Endogenous oils derived from human adipocytes are potent adjuvants that promote IL-1α-dependent inflammation. Diabetes 2014, 63, 2037-2050.
103. Hotamisligil, G. S., Inflammation and metabolic disorders. Nature 2006, 444, 860-867.
104. Lwow, F., Dunajska, K., Milewicz, A., Jedrzejuk, D. et al., Effect of moderate-intensity exercise on oxidative stress indices in metabolically healthy obese and metabolically unhealthy obese phenotypes in postmenopausal women: a pilot study. Menopause 2011, 18, 646-653.
105. Ali, F., Ismail, A., Kersten, S., Molecular mechanisms underlying the potential antiobesity-related diseases effect of cocoa polyphenols. Mol. Nutr. Food Res. 2014, 1, 33-48.
106. Flachs, P., Rossmeisl, M., Bryhn, M., Kopecky, J., Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin. Sci. (Lond) 2009, 1, 1-16.
107. Frey, S. K., Vogel, S., Vitamin A metabolism and adipose tissue biology. Nutrients 2011, 1, 27-39.
108. Rosa, F. T., Zulet, M. A., Marchini, J. S., Martinez, J. A., Bioactive compounds with effects on inflammation markers in humans. Int. J. Food Sci. Nutr. 2012, 6, 749-765.
109. Teng, K. T., Chang, C. Y., Chang, L. F., Nesaretnam, K., Modulation of obesity-induced inflammation by dietary fats: mechanisms and clinical evidence. Nutr. J. 2014, 13, 12.
110. Lu'o'ng, L. K., Nguyen, L. T., The beneficial role of vitamin D in obesity: possible genetic and cell signaling mechanisms. Nutr. J. 2013, 13, 89.
111. Wang, S., Moustaid-Moussa, N., Chen, L., Mo, H. et al., Novel insights of dietary polyphenols and obesity. J. Nutr. Biochem., 2014, 1, 1-18.
112. Munoz, A., Costa, M., Nutritionally mediated oxidative stress and inflammation. Oxid. Med. Cell Longev. 2013, 2013, 610950.
113. Aoyagi, R., Funakoshi-Tago, M., Fujiwara, Y., Tamura, H., Coffee inhibits adipocyte differentiation via inactivation of PPARgamma. Biol. Pharm. Bull. 2014, 37, 1820-1825.
114. Rustenbeck, I., Lier-Glaubitz, V., Willenborg, M., Eggert, F. et al., Effect of chronic coffee consumption on weight gain and glycaemia in a mouse model of obesity and type 2 diabetes. Nutr. Diabetes 2014, e123.
115. Jia, H., Aw, W., Egashira, K., Takahashi, S. et al., Coffee intake mitigated inflammation and obesity-induced insulin resistance in skeletal muscle of high-fat diet-induced obese mice. Genes Nutr. 2014, 9, 389.
116. Cano-Marquina, A., Tarin, J. J., Cano, A., The impact of coffee on health. Maturitas 2013, 1, 7-21.
117. O'Keefe, J. H., Bhatti, S. K., Patil, H. R., DiNicolantonio, J. J. et al., Effects of habitual coffee consumption on cardiometabolic disease, cardiovascular health, and all-cause mortality. J. Am. Coll. Cardiol. 2013, 12, 1043-1051.
118. Correa, T. A., Rogero, M. M., Mioto, B. M., Tarasoutchi, D. et al., Paper-filtered coffee increases cholesterol and inflammation biomarkers independent of roasting degree: a clinical trial. Nutrition 2013, 7-8, 977-981.
119. Yamashita, K., Yatsuya, H., Muramatsu, T., Toyoshima, H. et al., Association of coffee consumption with serum adiponectin, leptin, inflammation and metabolic markers in Japanese workers: a cross-sectional study. Nutr. Diabetes 2012, e33.
120. Folchetti, L. D., Monfort-Pires, M., de Barros, C. R., Martini, L. A. et al., Association of fruits and vegetables consumption and related-vitamins with inflammatory and oxidative stress markers in prediabetic individuals. Diabetol. Metab Syndr. 2014, 1, 22.
121. Yeon, J. Y., Kim, H. S., Sung, M. K., Diets rich in fruits and vegetables suppress blood biomarkers of metabolic stress in overweight women. Prev. Med. 2012, 54(Suppl), S109-S115.
122. Watzl, B., Kulling, S. E., Moseneder, J., Barth, S. W. et al., A 4-wk intervention with high intake of carotenoid-rich vegetables and fruit reduces plasma C-reactive protein in healthy, nonsmoking men. Am. J. Clin. Nutr. 2005, 5, 1052-1058.
123. Macready, A. L., George, T. W., Chong, M. F., Alimbetov, D. S. et al., Flavonoid-rich fruit and vegetables improve microvascular reactivity and inflammatory status in men at risk of cardiovascular disease-FLAVURS: a randomized controlled trial. Am. J. Clin. Nutr. 2014, 3, 479-489.
124. Navarro, S. L., Schwarz, Y., Song, X., Wang, C. Y. et al., Cruciferous vegetables had variable effects on biomarkers of systemic inflammation in a randomized controlled trial in healthy young adults. J. Nutr. 2014, 144, 1850-1857.
125. Almendingen, K., Brevik, A., Nymoen, D. A., Hilmarsen, H. T. et al., Modulation of COX-2 expression in peripheral blood cells by increased intake of fruit and vegetables? Eur. J. Clin. Nutr. 2005, 4, 597-602.
126. Freese, R., Vaarala, O., Turpeinen, A. M., Mutanen, M., No difference in platelet activation or inflammation markers after diets rich or poor in vegetables, berries and apple in healthy subjects. Eur. J. Nutr. 2004, 3, 175-182.
127. Chen, Z., Zhu, Q. Y., Tsang, D., Huang, Y., Degradation of green tea catechins in tea drinks. J. Agric. Food Chem. 2001, 1, 477-482.
128. Chan, C. Y., Wei, L., Castro-Munozledo, F., Koo, W. L., (-)-Epigallocatechin-3-gallate blocks 3T3-L1 adipose conversion by inhibition of cell proliferation and suppression of adipose phenotype expression. Life Sci. 2011, 21-22, 779-785.
129. Kim, H., Hiraishi, A., Tsuchiya, K., Sakamoto, K., (-) Epigallocatechin gallate suppresses the differentiation of 3T3-L1 preadipocytes through transcription factors FoxO1 and SREBP1c. Cytotechnology 2010, 3, 245-255.
130. Lin, J., Della-Fera, M. A., Baile, C. A., Green tea polyphenol epigallocatechin gallate inhibits adipogenesis and induces apoptosis in 3T3-L1 adipocytes. Obes. Res. 2005, 6, 982-990.
131. Monteiro, R., Assuncao, M., Andrade, J. P., Neves, D. et al., Chronic green tea consumption decreases body mass, induces aromatase expression, and changes proliferation and apoptosis in adult male rat adipose tissue. J. Nutr. 2008, 11, 2156-2163.
132. Hung, P. F., Wu, B. T., Chen, H. C., Chen, Y. H. et al., Antimitogenic effect of green tea (-)-epigallocatechin gallate on 3T3-L1 preadipocytes depends on the ERK and Cdk2 pathways. Am. J. Physiol Cell Physiol 2005, 5, C1094-C1108.
133. Lu, C., Zhu, W., Shen, C. L., Gao, W., Green tea polyphenols reduce body weight in rats by modulating obesity-related genes. PLoS One. 2012, 6, e38332.
134. Pico, C., Puigserver, P., Oliver, P., Palou, A., 2-Methoxyestradiol, an endogenous metabolite of 17beta-estradiol, inhibits adipocyte proliferation. Mol. Cell Biochem. 1998, 1-2, 1-7.
135. Wu, B. T., Hung, P. F., Chen, H. C., Huang, R. N. et al., The apoptotic effect of green tea (-)-epigallocatechin gallate on 3T3-L1 preadipocytes depends on the Cdk2 pathway. J. Agric. Food Chem. 2005, 14, 5695-5701.
136. Ashida, H., Furuyashiki, T., Nagayasu, H., Bessho, H. et al., Anti-obesity actions of green tea: possible involvements in modulation of the glucose uptake system and suppression of the adipogenesis-related transcription factors. Biofactors 2004, 1-4, 135-140.
137. Chen, Y. K., Cheung, C., Reuhl, K. R., Liu, A. B. et al., Effects of green tea polyphenol (-)-epigallocatechin-3-gallate on newly developed high-fat/Western-style diet-induced obesity and metabolic syndrome in mice. J. Agric. Food Chem. 2011, 21, 11862-11871.
138. Kovacs, E. M., Lejeune, M. P., Nijs, I., Westerterp-Plantenga, M. S., Effects of green tea on weight maintenance after body-weight loss. Br. J. Nutr. 2004, 3, 431-437.
139. Bogdanski, P., Suliburska, J., Szulinska, M., Stepien, M. et al., Green tea extract reduces blood pressure, inflammatory biomarkers, and oxidative stress and improves parameters associated with insulin resistance in obese, hypertensive patients. Nutr. Res. 2012, 6, 421-427.
140. Ueda, M., Ashida, H., Green tea prevents obesity by increasing expression of insulin-like growth factor binding protein-1 in adipose tissue of high-fat diet-fed mice. J. Agric. Food Chem. 2012, 36, 8917-8923.
141. Wheatcroft, S. B., Kearney, M. T., IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol. Metab 2009, 4, 153-162.
142. Tian, C., Ye, X., Zhang, R., Long, J. et al., Green tea polyphenols reduced fat deposits in high fat-fed rats via erk1/2-PPARgamma-adiponectin pathway. PLoS One 2013, 1, e53796.
143. Cunha, C. A., Lira, F. S., Rosa Neto, J. C., Pimentel, G. D. et al., Green tea extract supplementation induces the lipolytic pathway, attenuates obesity, and reduces low-grade inflammation in mice fed a high-fat diet. Mediators. Inflamm. 2013, 2013, 635470.
144. Chung, M. Y., Park, H. J., Manautou, J. E., Koo, S. I. et al., Green tea extract protects against nonalcoholic steatohepatitis in ob/ob mice by decreasing oxidative and nitrative stress responses induced by proinflammatory enzymes. J. Nutr. Biochem. 2012, 4, 361-367.
145. Basu, A., Du, M., Sanchez, K., Leyva, M. J. et al., Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome. Nutrition 2011, 2, 206-213.
146. Wang, X., Chai, H., Wang, Z., Lin, P. H. et al., Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Am. J. Physiol Heart Circ. Physiol 2008, 6, H2399-H2408.
147. Brown, A. L., Lane, J., Coverly, J., Stocks, J. et al., Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial. Br. J. Nutr. 2009, 6, 886-894.
148. Chuang, C. C., McIntosh, M. K., Potential mechanisms by which polyphenol-rich grapes prevent obesity-mediated inflammation and metabolic diseases. Annu. Rev. Nutr. 2011, 31, 155-176.
149. Fremont, L., Biological effects of resveratrol. Life Sci. 2000, 8, 663-673.
150. Chen, S., Xiao, X., Feng, X., Li, W. et al., Resveratrol induces Sirt1-dependent apoptosis in 3T3-L1 preadipocytes by activating AMPK and suppressing AKT activity and survivin expression. J. Nutr. Biochem. 2012, 9, 1100-1112.
151. Kwon, J. Y., Seo, S. G., Yue, S., Cheng, J. X. et al., An inhibitory effect of resveratrol in the mitotic clonal expansion and insulin signaling pathway in the early phase of adipogenesis. Nutr. Res. 2012, 8, 607-616.
152. Rivera, L., Moron, R., Zarzuelo, A., Galisteo, M., Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem.Pharmacol. 2009, 6, 1053-1063.
153. Kang, L., Heng, W., Yuan, A., Baolin, L. et al., Resveratrol modulates adipokine expression and improves insulin sensitivity in adipocytes: relative to inhibition of inflammatory responses. Biochimie 2010, 7, 789-796.
154. Kim, S., Jin, Y., Choi, Y., Park, T., Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem. Pharmacol. 2011, 11, 1343-1351.
155. Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H. et al., Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011, 5, 612-622.
156. Ahn, J., Lee, H., Kim, S., Ha, T., Resveratrol inhibits TNF-alpha-induced changes of adipokines in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2007, 4, 972-977.
157. Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Yanez-Gascon, M. J. et al., Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 2013, 1, 37-48.
158. Zhu, J., Yong, W., Wu, X., Yu, Y. et al., Anti-inflammatory effect of resveratrol on TNF-alpha-induced MCP-1 expression in adipocytes. Biochem. Biophys. Res. Commun. 2008, 2, 471-477.
159. Bujanda, L., Hijona, E., Larzabal, M., Beraza, M. et al., Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC. Gastroenterol. 2008, 8, 40.
160. Shang, J., Chen, L. L., Xiao, F. X., Sun, H. et al., Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol. Sin. 2008, 6, 698-706.
161. Jalil, A. M., Ismail, A., Pei, C. P., Hamid, M. et al., Effects of cocoa extract on glucometabolism, oxidative stress, and antioxidant enzymes in obese-diabetic (Ob-db) rats. J. Agric. Food Chem. 2008, 17, 7877-7884.
162. Ruzaidi, A., Amin, I., Nawalyah, A. G., Hamid, M. et al., The effect of Malaysian cocoa extract on glucose levels and lipid profiles in diabetic rats. J. Ethnopharmacol. 2005, 1-2, 55-60.
163. Grassi, D., Desideri, G., Necozione, S., Lippi, C. et al., Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J. Nutr. 2008, 9, 1671-1676.
164. Cordero-Herrera, I., Martin, M. A., Bravo, L., Goya, L. et al., Cocoa flavonoids improve insulin signalling and modulate glucose production via AKT and AMPK in HepG2 cells. Mol. Nutr. Food Res. 2013, 6, 974-985.
165. Yamashita, Y., Okabe, M., Natsume, M., Ashida, H., Prevention mechanisms of glucose intolerance and obesity by cacao liquor procyanidin extract in high-fat diet-fed C57BL/6 mice. Arch. Biochem. Biophys. 2012, 2, 95-104.
166. Ramiro-Puig, E., Castell, M., Cocoa: antioxidant and immunomodulator. Br. J. Nutr. 2009, 7, 931-940.
167. Sanbongi, C., Suzuki, N., Sakane, T., Polyphenols in chocolate, which have antioxidant activity, modulate immune functions in humans in vitro. Cell Immunol. 1997, 2, 129-136.
168. Noe, V., Penuelas, S., Lamuela-Raventos, R. M., Permanyer, J. et al., Epicatechin and a cocoa polyphenolic extract modulate gene expression in human Caco-2 cells. J. Nutr. 2004, 10, 2509-2516.
169. Lee, K. W., Kundu, J. K., Kim, S. O., Chun, K. S. et al., Cocoa polyphenols inhibit phorbol ester-induced superoxide anion formation in cultured HL-60 cells and expression of cyclooxygenase-2 and activation of NF-kappaB and MAPKs in mouse skin in vivo. J. Nutr. 2006, 5, 1150-1155.
170. Mao, T., Van De Water, J., Keen, C. L., Schmitz, H. H. et al., Cocoa procyanidins and human cytokine transcription and secretion. J. Nutr. 2000, 8S(Suppl), 2093S-2099S.
171. Monagas, M., Khan, N., Andres-Lacueva, C., Casas, R. et al., Effect of cocoa powder on the modulation of inflammatory biomarkers in patients at high risk of cardiovascular disease. Am. J. Clin. Nutr. 2009, 5, 1144-1150.
172. Puglisi, M. J., Hasty, A. H., Saraswathi, V., The role of adipose tissue in mediating the beneficial effects of dietary fish oil. J. Nutr. Biochem. 2011, 2, 101-108.
173. Kim, H. K., Della-Fera, M., Lin, J., Baile, C. A., Docosahexaenoic acid inhibits adipocyte differentiation and induces apoptosis in 3T3-L1 preadipocytes. J. Nutr. 2006, 12, 2965-2969.
174. Figueras, M., Olivan, M., Busquets, S., Lopez-Soriano, F. J. et al., Effects of eicosapentaenoic acid (EPA) treatment on insulin sensitivity in an animal model of diabetes: improvement of the inflammatory status. Obesity.(Silver. Spring) 2011, 2, 362-369.
175. Kalupahana, N. S., Claycombe, K., Newman, S. J., Stewart, T. et al., Eicosapentaenoic acid prevents and reverses insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue inflammation. J. Nutr. 2010, 11, 1915-1922.
176. Hsueh, H. W., Zhou, Z., Whelan, J., Allen, K. G. et al., Stearidonic and eicosapentaenoic acids inhibit interleukin-6 expression in ob/ob mouse adipose stem cells via Toll-like receptor-2-mediated pathways. J. Nutr. 2011, 7, 1260-1266.
177. Talukdar, S., Olefsky, J. M., Osborn, O., Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol. Sci. 2011, 9, 543-550.
178. Kralova, L. I., Suchanek, P., Brabcova, E., Kovar, J. et al., Effect of different types of dietary fatty acids on subclinical inflammation in humans. Physiol Res. 2013, 2, 145-152.
179. Kiecolt-Glaser, J. K., Belury, M. A., Andridge, R., Malarkey, W. B. et al., Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain Behav. Immun. 2012, 6, 988-995.
180. Itariu, B. K., Zeyda, M., Hochbrugger, E. E., Neuhofer, A. et al., Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial. Am. J. Clin. Nutr. 2012, 5, 1137-1149.
181. Wortman, P., Miyazaki, Y., Kalupahana, N. S., Kim, S. et al., n3 and n6 polyunsaturated fatty acids differentially modulate prostaglandin E secretion but not markers of lipogenesis in adipocytes. Nutr. Metab (Lond) 2009, 6, 5.
182. Wahli, W., Michalik, L., PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol. Metab. 2012, 7, 351-363.
183. Calder, P. C., n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 2006, 6(Suppl), 1505S-1519S.
184. Bonnans, C., Vachier, I., Chavis, C., Godard, P. et al., Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am. J. Respir. Crit Care Med. 2002, 11, 1531-1535.
185. Siriwardhana, N., Kalupahana, N. S., Cekanova, M., LeMieux, M. et al., Modulation of adipose tissue inflammation by bioactive food compounds. J. Nutr. Biochem. 2013, 4, 613-623.
186. Paniagua, J. A., Gallego, d. l. S., Romero, I., Vidal-Puig, A. et al., Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care 2007, 7, 1717-1723.
187. Shirakawa, J., Fujii, H., Ohnuma, K., Sato, K. et al., Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011, 4, 1246-1257.
188. Garcia-Escobar, E., Rodriguez-Pacheco, F., Garcia-Serrano, S., Gomez-Zumaquero, J. M. et al., Nutritional regulation of interleukin-6 release from adipocytes. Int. J. Obes. (Lond) 2010, 8, 1328-1332.
189. Granados, N., Amengual, J., Ribot, J., Palou, A. et al., Distinct effects of oleic acid and its trans-isomer elaidic acid on the expression of myokines and adipokines in cell models. Br. J. Nutr. 2011, 8, 1226-1234.
190. van Dijk, S. J., Feskens, E. J., Bos, M. B., Hoelen, D. W. et al., A saturated fatty acid-rich diet induces an obesity-linked proinflammatory gene expression profile in adipose tissue of subjects at risk of metabolic syndrome. Am. J. Clin. Nutr. 2009, 6, 1656-1664.
191. Wang, X., Cheng, M., Zhao, M., Ge, A. et al., Differential effects of high-fat-diet rich in lard oil or soybean oil on osteopontin expression and inflammation of adipose tissue in diet-induced obese rats. Eur. J. Nutr. 2013, 3, 1181-1189.
192. Harvey, K. A., Walker, C. L., Pavlina, T. M., Xu, Z. et al., Long-chain saturated fatty acids induce pro-inflammatory responses and impact endothelial cell growth. Clin.Nutr. 2010, 4, 492-500.
193. Huang, S., Rutkowsky, J. M., Snodgrass, R. G., Ono-Moore, K. D. et al., Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways. J. Lipid Res. 2012, 9, 2002-2013.
194. Wen, H., Gris, D., Lei, Y., Jha, S. et al., Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 2011, 5, 408-415.
195. Schaeffler, A., Gross, P., Buettner, R., Bollheimer, C. et al., Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling with innate immunity. Immunology 2009, 2, 233-245.
196. Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I. et al., TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest 2006, 11, 3015-3025.
197. Amyot, J., Semache, M., Ferdaoussi, M., Fontes, G. et al., Lipopolysaccharides impair insulin gene expression in isolated islets of Langerhans via Toll-Like Receptor-4 and NF-kappaB signalling. PLoS One. 2012, 4, e36200.
198. Murumalla, R. K., Gunasekaran, M. K., Padhan, J. K., Bencharif, K. et al., Fatty acids do not pay the toll: effect of SFA and PUFA on human adipose tissue and mature adipocytes inflammation. Lipids Health Dis. 2012, 11, 175.
199. Bjermo, H., Iggman, D., Kullberg, J., Dahlman, I. et al., Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am. J. Clin. Nutr. 2012, 5, 1003-1012.
200. Bogani, P., Galli, C., Villa, M., Visioli, F., Postprandial anti-inflammatory and antioxidant effects of extra virgin olive oil. Atherosclerosis 2007, 1, 181-186.
201. Camargo, A., Ruano, J., Fernandez, J. M., Parnell, L. D. et al., Gene expression changes in mononuclear cells in patients with metabolic syndrome after acute intake of phenol-rich virgin olive oil. BMC. Genomics 2010, 11, 253.
202. Garcia, O. P., Effect of vitamin A deficiency on the immune response in obesity. Proc. Nutr. Soc. 2012, 2, 290-297.
203. Cantorna, M. T., Nashold, F. E., Hayes, C. E., In vitamin A deficiency multiple mechanisms establish a regulatory T helper cell imbalance with excess Th1 and insufficient Th2 function. J. Immunol. 1994, 4, 1515-1522.
204. Austenaa, L. M., Carlsen, H., Hollung, K., Blomhoff, H. K. et al., Retinoic acid dampens LPS-induced NF-kappaB activity: results from human monoblasts and in vivo imaging of NF-kappaB reporter mice. J. Nutr. Biochem. 2009, 9, 726-734.
205. Luo, X. M., Ross, A. C., Physiological and receptor-selective retinoids modulate interferon gamma signaling by increasing the expression, nuclear localization, and functional activity of interferon regulatory factor-1. J. Biol. Chem. 2005, 43, 36228-36236.
206. Ziouzenkova, O., Orasanu, G., Sharlach, M., Akiyama, T. E. et al., Retinaldehyde represses adipogenesis and diet-induced obesity. Nat. Med. 2007, 6, 695-702.
207. Ziouzenkova, O., Plutzky, J., Retinoid metabolism and nuclear receptor responses: new insights into coordinated regulation of the PPAR-RXR complex. FEBS Lett. 2008, 1, 32-38.
208. Berry, D. C., Soltanian, H., Noy, N., Repression of cellular retinoic acid-binding protein II during adipocyte differentiation. J. Biol. Chem. 2010, 20, 15324-15332.
209. Kumar, M. V., Sunvold, G. D., Scarpace, P. J., Dietary vitamin A supplementation in rats: suppression of leptin and induction of UCP1 mRNA. J. Lipid Res. 1999, 5, 824-829.
210. Conde, J., Scotece, M., Gomez, R., Gomez-Reino, J. J. et al., At the crossroad between immunity and metabolism: focus on leptin. Expert Rev. Clin. Immunol. 2010, 5, 801-808.
211. Villaca, C. G., Pereira, S. E., Saboya, C. J., Ramalho, A., Non-alcoholic fatty liver disease and its relationship with the nutritional status of vitamin A in individuals with class III obesity. Obes. Surg. 2008, 4, 378-385.
212. Fung, G. J., Steffen, L. M., Zhou, X., Harnack, L. et al., Vitamin D intake is inversely related to risk of developing metabolic syndrome in African American and white men and women over 20 y: the Coronary Artery Risk Development in Young Adults study. Am. J. Clin. Nutr. 2012, 1, 24-29.
213. Tamer, G., Mesci, B., Tamer, I., Kilic, D. et al., Is vitamin D deficiency an independent risk factor for obesity and abdominal obesity in women? Endokrynol. Pol. 2012, 3, 196-201.
214. Lee, S., Lee, D. K., Choi, E., Lee, J. W., Identification of a functional vitamin D response element in the murine Insig-2 promoter and its potential role in the differentiation of 3T3-L1 preadipocytes. Mol. Endocrinol. 2005, 2, 399-408.
215. Kim, S. J., Choi, Y., Choi, Y. H., Park, T., Obesity activates toll-like receptor-mediated proinflammatory signaling cascades in the adipose tissue of mice. J. Nutr. Biochem. 2012, 2, 113-122.
216. Roth, C. L., Elfers, C. T., Figlewicz, D. P., Melhorn, S. J. et al., Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology 2012, 4, 1103-1111.
217. Sadeghi, K., Wessner, B., Laggner, U., Ploder, M. et al., Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur. J. Immunol. 2006, 2, 361-370.
218. Bahar-Shany, K., Ravid, A., Koren, R., Upregulation of MMP-9 production by TNFalpha in keratinocytes and its attenuation by vitamin D. J. Cell Physiol 2010, 3, 729-737.
219. Glowinska-Olszewska, B., Urban, M., Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism 2007, 6, 799-805.
220. Hashizume, K., Suzuki, S., Ichikawa, K., Takeda, T. et al., Effect of active vitamin D3 on the levels of NADPH-dependent cytosolic 3, 5, 3'-triiodo-L-thyronine-binding protein. Biochem.Biophys. Res. Commun. 1991, 1, 388-394.
221. Violi, F., Basili, S., Nigro, C., Pignatelli, P., Role of NADPH oxidase in atherosclerosis. Future Cardiol. 2009, 1, 83-92.
222. Moreno, J., Krishnan, A. V., Swami, S., Nonn, L. et al., Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 2005, 17, 7917-7925.
223. Aparna, R., Subhashini, J., Roy, K. R., Reddy, G. S. et al., Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha, 25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog. J. Cell Biochem. 2008, 5, 1832-1842.
224. Jiang, Q., Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radic. Biol. Med. 2014, 72, 76-90.
225. Cooney, R. V., Franke, A. A., Harwood, P. J., Hatch-Pigott, V. et al., Gamma-tocopherol detoxification of nitrogen dioxide: superiority to alpha-tocopherol. Proc. Natl. Acad. Sci. USA 1993, 5, 1771-1775.
226. Wang, Y., Jiang, Q., gamma-Tocotrienol inhibits lipopolysaccharide-induced interlukin-6 and granulocyte colony-stimulating factor by suppressing C/EBPbeta and NF-kappaB in macrophages. J. Nutr. Biochem. 2013, 6, 1146-1152.
227. Himmelfarb, J., Phinney, S., Ikizler, T. A., Kane, J. et al., Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J. Ren. Nutr. 2007, 5, 296-304.
228. Mahalingam, D., Radhakrishnan, A. K., Amom, Z., Ibrahim, N. et al., Effects of supplementation with tocotrienol-rich fraction on immune response to tetanus toxoid immunization in normal healthy volunteers. Eur. J. Clin. Nutr. 2011, 1, 63-69.
229. Wiser, J., Alexis, N. E., Jiang, Q., Wu, W. et al., In vivo gamma-tocopherol supplementation decreases systemic oxidative stress and cytokine responses of human monocytes in normal and asthmatic subjects. Free Radic. Biol. Med. 2008, 1, 40-49.
230. Rizzo, M. R., Abbatecola, A. M., Barbieri, M., Vietri, M. T. et al., Evidence for anti-inflammatory effects of combined administration of vitamin E and C in older persons with impaired fasting glucose: impact on insulin action. J. Am. Coll. Nutr. 2008, 4, 505-511.
231. Dalgard, C., Nielsen, F., Morrow, J. D., Enghusen-Poulsen, H. et al., Supplementation with orange and blackcurrant juice, but not vitamin E, improves inflammatory markers in patients with peripheral arterial disease. Br. J. Nutr. 2009, 2, 263-269.
232. Mocchegiani, E., Costarelli, L., Giacconi, R., Malavolta, M. et al., Vitamin E-gene interactions in aging and inflammatory age-related diseases: implications for treatment. A systematic review. Ageing Res. Rev. 2014, 14, 81-101.
233. Ohsaki, Y., Shirakawa, H., Hiwatashi, K., Furukawa, Y. et al., Vitamin K suppresses lipopolysaccharide-induced inflammation in the rat. Biosci. Biotechnol. Biochem. 2006, 4, 926-932.
234. Shea, M. K., Booth, S. L., Massaro, J. M., Jacques, P. F. et al., Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am. J. Epidemiol. 2008, 3, 313-320.